Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate, or extent of cytokine production contributing to an immune response. [GOC:add]
Negative regulation of cytokine production is a crucial process in the immune system that prevents excessive or inappropriate inflammatory responses. It involves a complex interplay of molecular mechanisms, ensuring a balanced and controlled immune response. Here's a detailed description:
**1. Signal Transduction Pathways:**
* **Cytokine receptors:** Cytokines, signaling molecules secreted by immune cells, bind to specific receptors on target cells, initiating intracellular signaling cascades. These pathways often involve the activation of transcription factors, leading to the production of genes involved in immune responses.
* **Inhibitory receptors:** Several inhibitory receptors are expressed on immune cells. These receptors engage with ligands, such as inhibitory cytokines or molecules on other immune cells, triggering signaling cascades that suppress downstream activation.
**2. Transcriptional Regulation:**
* **Transcription factors:** Transcription factors like NF-κB, AP-1, and STATs play pivotal roles in regulating cytokine gene expression.
* **Negative regulators:** Specific transcription factors, such as IκB, act as inhibitors of NF-κB, preventing its translocation to the nucleus and subsequent gene activation. Similarly, SOCS proteins can inhibit JAK-STAT signaling pathways.
* **Epigenetic modifications:** DNA methylation and histone modifications can alter gene expression, influencing cytokine production.
**3. Post-Translational Regulation:**
* **Protein degradation:** Cytokines can be targeted for degradation by the ubiquitin-proteasome system or by lysosomal pathways.
* **Protein phosphorylation:** Phosphorylation of specific residues on cytokines or their receptors can modulate their activity.
* **Secretion control:** Cytokine secretion can be regulated by controlling the trafficking of vesicles containing the cytokine.
**4. Cellular Interactions:**
* **Immune cell interactions:** Immune cells communicate through various mechanisms, including direct cell-cell contact and the release of soluble factors. These interactions can influence cytokine production.
* **Treg cells:** Regulatory T cells (Tregs) play a crucial role in suppressing immune responses. They produce inhibitory cytokines like IL-10 and TGF-β, dampening cytokine production by other immune cells.
**5. Molecular Mechanisms:**
* **Apoptosis:** Induction of apoptosis in immune cells can eliminate cytokine-producing cells.
* **Anti-inflammatory cytokines:** IL-10, TGF-β, and IL-35 are anti-inflammatory cytokines that suppress the production of pro-inflammatory cytokines.
* **Immune checkpoints:** Molecules like CTLA-4 and PD-1 act as immune checkpoints, inhibiting T cell activation and cytokine production.
**6. Pathological Implications:**
* **Autoimmune diseases:** Dysregulation of negative regulation can contribute to autoimmune diseases, where the immune system attacks its own tissues.
* **Infections:** Defects in negative regulation can lead to uncontrolled inflammation and susceptibility to infections.
* **Cancer:** Cancer cells can evade immune surveillance by manipulating negative regulatory mechanisms.
**In summary, negative regulation of cytokine production is a multifaceted process essential for maintaining immune homeostasis. It involves multiple levels of regulation, from signal transduction to cellular interactions, to ensure a controlled and appropriate immune response.**'
"
Protein | Definition | Taxonomy |
---|---|---|
Interleukin-10 | An interleukin-10 that is encoded in the genome of human. [PRO:JAN, UniProtKB:P22301] | Homo sapiens (human) |
Tumor necrosis factor | A tumor necrosis factor that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
mesalamine | mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug |
way 151693 | |||
pentoxifylline | oxopurine | ||
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases. | methoxybenzenes | |
rolipram | pyrrolidin-2-ones | antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | |
sulfasalazine | sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) | ||
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
birb 796 | aromatic ether; morpholines; naphthalenes; pyrazoles; ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator | |
ganoderic acid a | triterpenoid | ||
ganoderiol f | ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source | triterpenoid | |
1-(phenylmethyl)benzimidazole | benzimidazoles | ||
luteolin-7-glucoside | luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum | beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone | antioxidant; plant metabolite |
apigetrin | apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. apigetrin: structure given in first source | beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative | antibacterial agent; metabolite; non-steroidal anti-inflammatory drug |
calycosin-7-o-beta-d-glucopyranoside | calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage. calycosin-7-O-beta-D-glucoside: from Radix Astragali | 4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative | |
spd-304 | SPD-304: structure in first source | ||
ganoderic acid f | ganoderic acid F: isolated from Ganoderma lucidum; structure in first source | triterpenoid | |
ganoderic acid c2 | ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source | triterpenoid | |
hg-9-91-01 | HG-9-91-01 : A member of the class of phenylureas that is a potent inhibitor of salt-inducible kinase 2, a potential target protein for therapy in ovarian cancer. HG-9-91-01: inhibits salt-inducible kinases; structure in first source | aminopyrimidine; dimethoxybenzene; N-alkylpiperazine; N-arylpiperazine; phenylureas; secondary amino compound | antineoplastic agent; salt-inducible kinase 2 inhibitor |